Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

China’s VNA & PACS Market by Department, Enterprise, Delivery Mode, Vendor, End-user – Forecast to 2023 – ResearchAndMarkets.com

Published

on

Reading Time: 4 minutes

DUBLIN–(BUSINESS WIRE)–The “China
VNA and PACS Market by Department, Enterprise, Delivery Mode, Vendor,
End User – Forecast to 2023”
report has been added to ResearchAndMarkets.com’s
offering.

China Vendor Neutral Archive (VNA) & Picture Archiving and Communication
System (PACS) market is expected to grow at a CAGR of 14.2% from 2018 to
2023.

The market is driven by factors such as favorable healthcare reforms,
growing economy and disposable income, rising geriatric imaging volumes,
growing adoption of advanced medical technologies and health IT, and
increasing installation of diagnostic imaging modalities.

In addition, penetration of artificial intelligence in medical imaging,
rapidly growing field of telehealth, and adoption of advanced modalities
especially in Level III hospitals provides a significant opportunity for
PACS & VNA market growth during the forecast period.

Country Outlook

Healthcare system in China has tremendous potential. The rapid
technological development along with improving the living standard of
China’s growing middle and upper classes has resulted in the growing
adoption of advanced and hi-tech solutions by the hospitals. In
addition, the government’s focus also triggers the market growth to some
extent.

For instance, the domestic healthcare industry has started supporting
healthcare AI startups in China, providing them with easier access to
healthcare data to train their algorithms, assisted by the relatively
flexible regulations. Technological advancements such as big data and
artificial intelligence in machine learning are going to lead the
medical imaging market in China, thereby bolstering the VNA & PACS
market in the coming years.

Key Findings

Vendor Neutral Archive (VNA) to Witness Fastest Growth

PACS dominates the market as it has been traditionally adopted in the
field of radiology, cardiology, and other departments to replace
film-based image retrieval, distribution, and display. However, the VNA
segment is expected to grow at the fastest CAGR during the forecast
period.

Departmental PACS Dominates the China Picture Archiving and
Communication System (PACS) Market

Departmental PACS market held the largest share of Picture Archiving and
Communication System (PACS) market in China. The factors such as
increasing pressure to improve care quality, growing efforts to enhance
the patient experience and reduce costs, the emerging field of
telehealth, and growing applications of imaging in other specialties
than radiology support the demand for departmental PACS in the country.

Hospitals dominate the China VNA/PACS market and also
Witness Largest Demand Through 2023

Hospitals were the leading adopters of PACS & VNA in China and commanded
the largest share of this market. The largest share and highest CAGR of
this segment are primarily attributed to a significant number of Chinese
citizens being treated in hospitals, growing number of private
hospitals, greater budget to implement advanced solutions such as PACS,
rising aging population and burden of chronic diseases such as cancer,
and growing health IT investments in hospitals.

Hospitals are further segmented into public hospitals and private
hospitals. Public hospitals are further segmented into tier I, tier II,
and tier III hospitals. Tier III hospitals commanded the largest share
of VNA & PACS market in China, owing to changing the economy and
increasingly middle-class population, advanced specialists and
equipment, increasing prevalence of cancer, the demand of better
healthcare services, public trust towards Level III Hospitals, and
access to state-of-the-art technology.

Key Players

The report includes competitive landscape based on extensive assessment
of the key strategic developments adopted by leading market participants
in the industry over the past 3 years (2015-2018).

Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

4.1. Introduction

4.2. Drivers

4.2.1. Favorable Healthcare Reforms

4.2.2. Growing Economy and Disposable Income

4.2.3. Rising Geriatric Imaging Volumes

4.2.4. Growing Adoption of Advanced Medical Technologies and Health IT

4.2.5. Increasing Installation of Diagnostic Imaging Modalities

4.3. Restraints

4.3.1. Disparities Between Urban And Rural Area Healthcare Facilities

4.3.2 Dearth of Skilled Professionals

4.3.3 Lack of Interoperability

4.4. Opportunities

4.4.1. Penetration of Artificial Intelligence in Medical Imaging

4.4.2. Rapidly Growing Field of Telehealth

4.4.3. Adoption of Advanced Modalities especially in Level III Hospitals

4.5. Trends

4.5.1. Rising Hospital Privatization

4.5.2. Focus on Development of Diagnostic Imaging Centers

4.5.3 Digital Health Initiatives in China

4.6 Market Share Analysis, by key players

5. China PACS & VNA Market, By Type

5.1 Introduction

5.2 PACS

5.3 VNA

6. China PACS Market, By Procurement Model

6.1. Introduction

6.2. Departmental PACS

6.2.1 Radiology PACS

6.2.2 Cardiology PACS

6.2.3 Others

6.3. Enterprise PACS

7. China PACS Market, By Delivery Model

7.1. Introduction

7.2. On-Premise PACS

7.3. On demand PACS (web/cloud/hybrid)

8. China VNA Market, By Procurement Model

8.1. Introduction

8.2. Enterprise VNA

8.2.1. Multi-Departmental VNA

8.2.2. Multi-Site VNA

8.3. Departmental VNA

9. China VNA Market, By Delivery Model

9.1. Introduction

9.2. On-Premise VNA

9.3. Hybrid VNA

9.4. Fully Cloud-Based VNA

10. China VNA Market, By Vendor Type

10.1. Introduction

10.2. PACS Vendors

10.3. Independent Software Vendors

10.4. Infrastructure Vendors

11. China VNA & PACS Market, By End User

11.1. Introduction

11.2. Hospitals

11.2.1 Public Hospitals

11.2.1.1 Tier I Hospitals

11.2.1.2 Tier II Hospitals

11.2.1.3 Tier III Hospitals

11.2.2 Private Hospitals

11.3. Diagnostic Imaging Centers

11.4. Others

12. Company Profiles

12.1. Xi’an Huahai Medical Info-Tech Co. Ltd.

12.1.1. Business Overview

12.1.2. Financial Overview

12.1.3. Product Portfolio

12.1.4. Strategic Developments

12.2. EBM Technologies Inc.

12.3. Beijing Tianjian Source Technology Co. Ltd.

12.4. Neusoft Corporation

12.5. GE Healthcare

12.6. Shenzhen Mindray Bio-Medical Electronics Co. Ltd.

12.7. Winning Health Technology Group Co.

12.8. Carestream Health

12.9. FUJIFILM Corporation

12.10. INFINITT Healthcare Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/kz90u3

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: E-Healthcare,
Medical
Imaging


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Published

on

innocan-pharma-announces-study-findings-that-lpt-cbd-maintains-its-prolonged-release-in-rabbits

HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.   

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.

Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.   

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-study-findings-that-lpt-cbd-maintains-its-prolonged-release-in-rabbits-302069807.html

Continue Reading

SCHWAZZE

Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer

Published

on

schwazze-appoints-forrest-hoffmaster-as-interim-chief-executive-officer

DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.

Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.

“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-appoints-forrest-hoffmaster-as-interim-chief-executive-officer-302069402.html

Continue Reading

Cannabis

Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028

Published

on

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania